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Abstract: The growing problem of antimicrobial resistance (AMR) has led to calls for antimicrobial
stewardship programs (ASP) to control antibiotic use in healthcare settings. Key strategies include
prospective audit with feedback and intervention, and formulary restriction and preauthorization.
Education, guidelines, clinical pathways, de-escalation, and intravenous to oral conversion are also
part of some programs. Impact and quality of ASP can be assessed using process or outcome measures.
Outcome measures are categorized as microbiological, patient or financial outcomes. The objective
of this review was to provide an overview of quality measures for assessing ASP and the reported
impact of ASP in peer-reviewed studies, focusing particularly on patient outcomes. A literature search
of papers published in English between 1990 and June 2015 was conducted in five databases using a
combination of search terms. Primary studies of any design were included. A total of 63 studies were
included in this review. Four studies defined quality metrics for evaluating ASP. Twenty-one studies
assessed the impact of ASP on antimicrobial utilization and cost, 25 studies evaluated impact on
resistance patterns and/or rate of Clostridium difficile infection (CDI). Thirteen studies assessed impact
on patient outcomes including mortality, length of stay (LOS) and readmission rates. Six of these
13 studies reported non-significant difference in mortality between pre- and post-ASP intervention,
and five reported reductions in mortality rate. On LOS, six studies reported shorter LOS post
intervention; a significant reduction was reported in one of these studies. Of note, this latter study
reported significantly (p < 0.001) higher unplanned readmissions related to infections post-ASP.
Patient outcomes need to be a key component of ASP evaluation. The choice of metrics is influenced
by data and resource availability. Controlling for confounders must be considered in the design
of evaluation studies to adequately capture the impact of ASP and it is important for unintended
consequences to be considered. This review provides a starting point toward compiling standard
outcome metrics for assessing ASP.
Keywords: antimicrobial stewardship; antimicrobial resistance; quality indicators; outcome; patient;
infectious diseases
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1. Introduction
Antimicrobial resistance (AMR) is a growing public health threat which has attracted the
attention of national and international bodies. A recent World Health Organization (WHO)
surveillance of resistance to antibacterial drugs in bacteria commonly associated with hospital and
community infections revealed increasing resistance and/or decreased susceptibilities in the studied
bacteria [1]. Resistance of Escherichia coli to third-generation cephalosporins and fluoroquinolones
and Staphylococcocus aureus to methicillin (Methicillin Resistant Staphylococcous aureus, MRSA) are
reported to be 50% or more in five out of the six WHO regions [1]. Klebsiella pneumoniae resistance
to third-generation cephalosporins is reported to be greater than 50% in all six WHO regions.
Carbapenem-resistant K. pneumoniae is reportedin all WHO regions, with reports in two regions
exceeding 50%. Also, non-susceptibility of Streptococcus pneumoniae to penicillin is reported to be
more than 50% in all six WHO regions. A related English AMR surveillance report revealed increased
resistance of E. coli and K. pneumoniae to ciprofloxacin, third-generation cephalosporins, gentamicin,
and imipenem/meropenem [2]. The report however indicated decreased resistance of Pseudomonas
aeruginosa to ceftazidime, gentamicin, and imipenem/meropenem [2]. Recent reports highlightthat
patients with infection caused by drug resistant bacteria have a two-fold increase in mortality compared
to those with infection with sensitive bacteria [1,3].
Available estimates indicate that between 25%–50% of hospitalized patients receive antibiotics,
with between 30% and 50% of antibiotic use being inappropriate [4,5]. Published literature
demonstrates a strong link between antibiotic use and the development of resistance [3,6–8].
Antimicrobial stewardship programs are therefore quality motivated interventions aimed at improving
the use of antibiotics in healthcare facilities. The primary goal is to optimize clinical outcomes and
minimize unintended consequences such as Clostridium difficile infection (CDI) and resistance [4,9].
Strategies to achieve these goals have included prospective audit with intervention and feedback, and
formulary restriction and preauthorization. Supplemental strategies include education, guidelines
and clinical pathways, antimicrobial cycling and scheduled antimicrobial switch, antimicrobial order
forms, automatic stop orders, combination therapy, streamlining or de-escalation of therapy, dose
optimization, conversion from parenteral to oral therapy, and computer surveillance and decision
support [4,10].
A Cochrane review of interventions to improve antibiotic prescribing for hospital inpatients
classified these strategies into three main groups namely:
i persuasive interventions: these include education, audit and feedback, guidelines and
clinical pathways.
ii restrictive interventions: formulary restriction, prior approval or preauthorization from infectious
diseases (ID) physician, microbiologist or pharmacists, automatic stop orders, antimicrobial
cycling or scheduled switch, antibiotic order forms.
iii structural interventions: computerized records, computerized decision support, example
computer physician order entry (CPOE) [11].
Effective antimicrobial stewardship programs require a multidisciplinary team with responsibility
for promoting prudent antimicrobial use. The Infectious Diseases Society of America and the Society for
Healthcare Epidemiology of America (IDSA/SHEA) ASP guidelines [4] recommend a multidisciplinary
team which includes an ID physician and a clinical pharmacist with infectious diseases training as
core members. Inclusion of a clinical microbiologist, information system specialist, infection control
specialist, hospital epidemiologist, and hospital administrator is considered optimal. The English
antimicrobial stewardship (AMS) toolkit: “Start Smart, then Focus” recommends other core members
should be present, an acute care physician, a surgeon, a senior member of the pharmacy management
team, an anesthetist, a pediatrician, and a senior nurse [12].
There is an increased call on healthcare organizations to develop quality measures or indicators
to monitor and evaluate the impact of ASP [4,12–14]. Previous reviews have reported on the impact of
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ASP in reducing antimicrobial cost, AMR, superinfection, and patient outcomes (such as length of stay
(LOS), readmission rate, and mortality) [11,15]. The objective of this review was to provide an overview
of reported quality measures for assessing ASP and report on the impact of published antimicrobial
stewardship studies on these measures, with particular focus on patient outcome measures.
2. Methods
A literature search of papers published in English between the 1990 and June 2015 was identified
through a search of five databases: Scopus, Medline, CINAHL, Pubmed, and Embase using the
following search terms: (“antimicrobial stewardship” OR “antimicrobial stewardship program” OR
“antibiotic control program” OR “antibiotic policy” OR “antibiotic management program”); (outcomes
OR impact OR "quality measure" OR “performance measures” OR “length of stay” OR “clinical
improvement” OR “C. difficile infection” OR mortality OR resistance OR readmission OR MRSA).
Study Inclusion and Exclusion Criteria
Only primary research studies, published in English and which met the following criteria
were included:
‚ Defined and/or developed quality measures for assessing ASP in hospital settings.
‚ Used quality performance measures (such as change in antimicrobial use) and outcome measures
(including resistance patterns, rates of CDI, LOS, readmission, mortality, and cost savings) in
evaluating impact of ASP.
‚ Involved adult inpatients in acute and community hospital settings.
Studies excluded were:
‚ Those that reported prevalence of ASP without evaluation of impact.
‚ ASP studies in pediatrics and long term care facilities.
3. Results
The initial search returned 4319 articles. Of these, 152 met the inclusion criteria, and a full-text
evaluation was carried out on 63 studies. In summary, four studies defined quality metrics for
evaluating ASP. Twenty-one studies assessed impact on antimicrobial utilization and cost, 25 studies
evaluated impact on resistance patterns and/or rate of CDI. Thirteen studies assessed impact on
patient outcomes including mortality, LOS, and readmission rates.
3.1. Studies that Defined Quality Measures for Evaluating ASP
Table 1 includes studies [16–19] that developed or defined quality measures for evaluating ASP.
Methods used were modified Delphi technique, survey, and interviews. Bumpass et al. [19] surveyed
ID physicians’ and pharmacists’ opinions of AMS metrics considered important in evaluating ASP.
The authors reported that although appropriateness of antimicrobial use, infection-related mortality,
and antibiotic associated length of stay were considered more important outcomes by those surveyed,
antimicrobial use and cost were the most commonly collected metrics.
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Table 1. Studies that defined quality measures for evaluating antimicrobial stewardship programs
antimicrobial stewardship programs (ASP).
Study Method Used Category of Measure Quality Measures Identified
Nathwani et al.,
2002 [16] Expert panel
Process measures for
glycopeptideprescribing
i total number of glycopeptide in defined
daily dose (DDD)/1000-patient days
ii number of alert antibiotic forms
completed for glycopeptide
iii number of patients prescribed
glycopeptide appropriately according
to policy
iv number of patients prescribed
glycopeptide inappropriately
Chen et al.,
2011 [17]
Survey by questionnaireand
interviews Process and outcome
i DDD/1000 patient-days against state or
national data
ii quantity of antimicrobial use
within hospital
iii number of prescriptions of restricted
antibiotic complaints with
approved guideline.
iv cost savings
Morris et al.,
2012 [18] Modified Delphi Process and outcome
i days of therapy/1000 patient-days
ii number of patients with specific
organisms that are drug resistant
iii mortality related to
antimicrobial-resistant organisms
iv conservable days of therapy among
patients with community-acquired
pneumonia (CAP), skin and soft-tissue
infections (SSTI), or sepsis and
bloodstream infections (BSI)
v unplanned hospital readmission within
30 days after discharge from the
hospital in which the most responsible
diagnosis was one of CAP, SSTI, sepsis
or BSI
Bumpass et al.,
2014 [19] Survey Process and outcome
i appropriateness of antimicrobial use
ii infection-related mortality rate
iii antibiotic-associated length of stay
iv antimicrobial use
v antimicrobial cost
DDD—Defined daily dose.
3.2. Impact of ASP on Quality Measures
Impact of ASP on different quality measures is summarized in Tables 2–4. This is grouped into:
‚ impact on antimicrobial use and cost savings
‚ impact on C. difficile infection and resistance patterns
‚ impact on patient outcomes (LOS, readmission rate, mortality)
Some of the studies used more than one measure in assessing impact and majority (29) employed
before-after or pre-post-intervention (quasi-experimental) design without control. The pre-phase
consisted of retrospective collection of baseline data before ASP implementation.
3.2.1. Impact of ASP on Antimicrobial Use and Cost of Antimicrobials
Change in the use of specific antibiotic or antibiotic class is considered a process measure [4,20].
The majority of the programs that assessed impact of ASP on antibiotic use also assessed cost
savings. Twenty-one studies assessed impact on antimicrobial use and/or cost. The majority of
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the studies that reported significant cost savings did not provide the cost of implementing the program.
Table 2 summarizes studies [21–41] that assessed the impact of ASP on antimicrobial use and cost
of antimicrobials.
Table 2. Impact of ASP on antimicrobial use and cost of antimicrobials.
Study Setting AMS Strategy Design Results
Mercer et al.,
1999, USA [21]
450-bed community
hospital
Restriction,
pre-authorization,
clinical pathway
Before-after
Cost of IV and oral antibiotics reduced
by 26% and 10% respectively. Use of
high cost IV antibiotics reduced by 22%.
Bassetti et al.,
2000, Italy [22]
2500-bed teaching
hospital
Formulary restriction,
sequential therapy. Before-after
Cost of antibiotics decreased by 10.5%
following formulary introduction with
cost savings of €345,000. Ceftazidime
cost reduced by 52%, and antibiotic cost
per day of hospital stay decreased from
€4.53 to €4.18.
Berlid et al. 2001,
Norway [23]
600-bed acute
hospital Guidelines, education
Prospective
before-after
23% reduction in use of broad-spectrum
antibiotics. Cost of antibiotic reduced by
27% and 32% in the first and second year
of the program respectively.
Ansari et al. 2003,
Scotland, UK [24]
900-bed
University-affiliated
hospital
Guideline, review and
feedback
Before-after with
interrupted time
series (ITS)
Cost savings from targeted antibiotics
was (£133,269) (p < 0.0001). Cost of
program was £20,133. Use of targeted
antibiotic reduced by 0.27 DDD/100
bed-days/month.
Cook et al., 2004,
USA [25]
730-bed university
teaching hospital
Restriction,
pre-authorization,
review and feedback
Before-after
Broad spectrum antibiotic use decreased
by 28% with no change in susceptibilities
of common nosocomial gram-negative
organisms.
Mcgregor et al.,
2006, USA [26]
648-bed,
tertiary-care referral
center
Computerized decision
support system, review
and feedback
Randomized
controlled trial
Cost savings of $84,194 (23%) in the
intervention group.
Siddiqui et al.,
2007, Pakistan
[27]
12-bed adult ICU at
a teaching hospital
Restriction policy, stamp
on chart, feedback Before- after
34% reduction in use of broad spectrum
antibiotics and 40% cost reduction.
Cheng et al. 2009,
Hong Kong [28]
1500-bed university-
affiliated hospital
Guidelines, education,
feedback Before-after
Antimicrobial use reduced from 73.06
(baseline) to 64.01 DDD/1000
patient-days.Reduction in
broad-spectrum intravenous and total
antibiotics expenditure.
Teo et al., 2012,
Singapore [29]
1700-bed teaching
hospital
Guidelines, algorithm,
review, audit and
feedback,
Before-after
9.9% decrease in antibiotic consumption
(p = 0.032) with cost savings of $198,575
for the hospital, and $91,194 for patients.
Michaels et al.,
2012, USA [30]
236-bed acute-care
community
hospital
Restriction, review and
feedback, guidelines,
education
Before-after
Antimicrobial use decreased from 821.33
DDD/1000 patient-days to 778.77
DDD/1000 patient-days. Cost savings
approached $290,000 from reduction in
antibiotic expenditure.
Hagert et al.,
2012, USA [31]
39-bed acute care
and 38-bed
community
hospital
Computerized decision
support system, review
and feedback
Retrospective
(before-after) chart
review
Percentage of patients on antimicrobial
decreased from 36.8% to 25% (p < 0.001).
Total inpatient antimicrobial costs
decreased by $48,044
Vettese et al.,
2013, USA [32]
253-bed
Community
hospital
IV to oral conversion,
dose optimization,
review
Before-after
6.4% decline in days of therapy and a
37% reduction in total
antimicrobial expenditure.
Cisneros et al.,
2014, Spain [33]
1251-bed teaching
hospital
Education and training,
guidelines, counseling
interviews, feedback
Before-after
Reduction in antimicrobial consumption
from 1150 DDD/1000 patient-days to 852
DDD/1000 patient-days with 42%
reduction in antimicrobial expenditure.
Borde et al., 2014,
Germany [34]
1600-bed teaching
hospital
Guidelines revision
information and
education, review and
feedback
Before-after with
interrupted time
series
Significant decline in overall antibiotic
use (p < 0.0001), significant decrease in
cephalosporins and fluoroquinolones
use (p < 0.001).
Bartlett & Siola,
2014, USA [35]
155-bed community
hospital
Formulary restriction, IV
to oral conversion,
automatic stop, review
and feedback
Before-after
Acquisition costs decreased by 25.5%,
from $569,786 to $424,433 with a direct
cost savings of $145,353. Antimicrobial
use decreased from 1627 to 1338
DDD/1000 patient-days, a decrease
of 17.8%.
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Table 2. Cont.
Study Setting AMS Strategy Design Results
Hou et al., 2014,
China [36]
12-bed ICU of a
700-bed tertiary
teaching hospital
Education, formulary
restriction &
preauthorization
Before-after
Total ICU antibiotic consumption
decreased from 197.65 to 143.41
DDD/100 patient-days with
improvement in bacterial resistance.
Hospital-wide consumption also
decreased from 69.69 DDDs to 50.76
(27.16% decrease)
Palmay et al.,
2014, Canada [37]
6 clinical service
sections at a
1275-bed university
hospital
Education, audit and
feedback
Stepped-wedge
randomized trial
ASP intervention was associated with
21% reduction in targeted antimicrobial
(p = 0.004) with no reduction in cost and
microbiological outcomes.
Chandy et al.,
2014, India [38]
2140-bed teaching
hospital
Antibiotic policy
guidelines
Segmented time
series
Overall antibiotic use increased at a
monthly rate in segments 1, 2 & 3 of the
study but drop significantly in monthly
antibiotic use in segment 5.
Fukuda et al.,
2014, Japan [39]
429-bed community
hospital
Prospective audit with
intervention and
feedback, dose
optimization,
de-escalation
Before-after
25.8% decrease in antimicrobial cost
(p = 0.005), 80.0% decrease in
aminoglycosides use (p < 0.001).
Cook & Gooch,
2015, USA [40]
904-bed,
tertiary-care
teaching hospital
Restriction and prior
approval, review and
feedback, automatic
stop
Prospective
interventional
Total antimicrobial use decreased by
62.8% (p < 0.0001). Aminoglycosides use
decreased by 91.3% (p < 0.0001),
cephalosporins decreased by 68.3%
(p < 0.0001), extended-spectrum
penicillins decreased by 77.7%
(p < 0.0001), quinolones by 78.7%
(p < 0.0001). Antifungal use decreased by
71.0% (p < 0.0001) during 13-year
study period.
Taggart et al.,
2015, Canada [41]
2 ICUs at a 465-bed
teaching hospital Audit and feedback
Controlled
before-after
withinterrupted
time series
Total monthly antimicrobial use in one of
the ICUs decreased by 375 DDD/1000
patient-days (p < 0.0009)
after intervention.
3.2.2. Impact of ASP on Resistance Patterns and Clostridium Difficile Infection (CDI)
A total of 25 studies [42–66] assessed the impact of ASP on microbiological outcomes (bacterial
resistance patterns) and/or CDI rates. Thirteen of the 25 studies assessed impact on CDI rates and
other outcomes. Nine out of 13 studies reported a statistically significant reduction in the rate of
CDI following ASP implementation [41,42,51,52,54,56,58,61,64]. Khan and Cheesbrough [44] and
Malani et al. [62] reported a progressive fall in the rate of C. difficile-associated diarrhea (CDAD) and
50% decrease in the likelihood of developing CDI respectively. A restriction policy on ciprofloxacin
and ceftriaxone resulted in a 70.20% reduction in the CDI with non-significant effect on extended
spectrum beta lactamases (ESBL)—producing colliforms (p = 0.075) [63]—a proxy for antimicrobial
resistance development.
Twelve studies assessed the impact on the resistance patterns of organisms commonly associated
with hospital infections (ESKAPE: Enterococcus faecium, Staphylococcocus aureus, Klebsiella pneumoniae,
Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter species, e.g., Escherichia coli) [67]
and reported a reduction in resistance or unchanged susceptibilities in these organisms following
AMS interventions. Saizy-Callaert et al. [45] reported a significant fall in the rate of ESBL-producing
Enterobacteriaceae (p < 0.001) following the development of a multidisciplinary consultative approach
which included developing local prescribing consensus with all prescribers; restricted prescriptions
policy; regular audits of use of restricted antibiotics and institutional wide training and information
for prescribers. A restriction policy on ceftazidime resulted in a significant decrease in A. baumannii
(p = 0.01) [48]. Table 3 summarizes studies that assessed impact on CDI rate and resistance patterns.
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Table 3. Impact of ASP on resistance patterns and C. difficile infection.
Study Setting AMS Strategy Design Results
McNulty et al., 1997,
UK [42]
Elderly unit at a600-bed
district hospital
Guideline, restriction
following outbreak of
CDI
Before-after
CDAD cases fell from 37 to 16
following restriction of
cefuroxime.
Carling et al., 2003,
USA [43]
University-affiliated
teaching hospital
Formulary,
Prospectivemonitoring
Prospective
interventional
Significant fall in rates of CDI and
Enterobacteriaceae infections,
(p = 0.002 and p = 0.02)
respectively during 7 years
of ASP.
Khan &
Chessbrough 2003,
UK [44]
800-bed district hospital Formulary change, IV tooral conversion Before-after
Progressive fall in incidence of
CDAD over 5-year period.
Saizy-Callaert et al.,
2003, France [45]
600-bed hospital with 5
teaching department
Guideline, restriction,
training, feedback Before-after
Significant fall in ESBL-producing
Enterobacteriaceae (p < 0.001).
MRSA and CRP rates
remained stable.
Bantar et al., 2003,
Argentina [46]
250-bed teaching
hospital for adults
Antibiotic order form,
feedback, education,
prescription change
Prospective
interventional
NS change in resistance of E. coli
and K. pneumoniae to
3rd-generation cephalosporins,
but decreasing resistance of P.
mirabilis and E. cloacae observed.
Imipenem-resistant P. aeruginosa
decreased to 0%.
Martin et al., 2005,
USA [47] University hospital
Guidelines, formulary
restriction
Prospective
interventional
Increased susceptibility of P.
aeruginosa to
piperacillin/tazobactam,
ceftazidime and fluoroquinolones.
3% reduction in MRSA rate and
decreased resistance of K.
pnuemoniae to ceftazidime.
Brahmi et al., 2006,
Tunisia [48] 12-bed ICU Ceftazidime restriction Before-after
Significant (p = 0.01) decrease in
A. baumannii to ceftazidime.
Considerable reduction in
ESBL-producing K.
pneumoniaeresistance
to ceftazidime.
Ntagiopoulos et al.,
2007, Greece [49]
12-bed ICU of 700-bed
university-affiliated
general hospital
Restriction of
fluoroquinolones and
ceftazidime
Before-after
Significant increase in
susceptibilities of A. baumannii, P.
aeruginosa and K. pneumoniae to
ciprofloxacin (p < 0.01).
Mach et al., 2007,
Czech Republic [50] 500-bed general hospital
Guidelines, restriction,
education Before-after
NS decrease in resistance to
restricted antimicrobials, and NS
increase in resistance to
non-restricted antimicrobials.
Decreased resistance of E.
aerogenesand K. pneumoniae to
ofloxacin, gentamicin
and ceftazidime.
Fowler et al., 2007,
UK [51]
Three acute-care wards
for elder at a 1200-bed
tertiary hospital
Narrow-spectrum’
antibiotic policy,
feedback, cephalosporin
restriction
Before-after with
ITS
Significant (p = 0.009) fall in CDI,
no reported rise in infection
control procedures; MRSA
remained unchanged (p = 0.32).
Valiquet et al.,2007,
Canada [52]
683-bed
secondary/tertiary care
hospital
Guidelines, education Before-after withITS
Significant (p = 0.007) fall in
CDAD incidence, no change
(p = 0.63) following enhanced
infection control.
Ozorowski et al.,
2009, Poland [53]
120-bed hematology and
blood transfusion
tertiary care center
Guidelines, education Before-after
Successful control of VRE
outbreak and improvement in the
resistance patterns of
gram-negative bacteria.
Talpaert et al., 2011,
[54]
450-bed university
affiliated general
hospital
Guideline and
restriction of ‘high-risk’
antibiotics, education
Quasi-experimental
with ITS
Significant fall in CDI incidence
(p < 0.0001).
Altunsoy et al., 2011,
Turkey [55]
Nation-wide restriction
program Before-after
Decrease in MRSA rates from 44%
to 41%. Decrease in the use of
carbapenems correlated with
decrease in carbapenem-resistant
Pseudomonas and
Acinetobacter species.
Cook et al., 2011 [56] 861-bed universityteaching hospital EMR implementation
Before-after with
ITS
18.7% decrease in CDI (p = 0.07)
and 45.2% decrease in MRSA
(p < 0.0001).
Niwa et al., 2012,
Japan [57]
606-bed university
hospital
Prospective review,
guidelines,
de-escalation, education
Before-after
Significant reduction in MRSA
and Serratia marcescens occurrence
(p = 0.026 and p = 0.026)
respectively. NS decrease in P.
aureginosa resistant to ceftazidime
and piperacillin.
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Table 3. Cont.
Study Setting AMS Strategy Design Results
Aldeyab et al., 2012,
UK [58] 233-bed hospital
Revised antibiotic policy
that avoided ‘high-risk’
antibiotics
Retrospective
intervention with
ITS
Significant decrease in CDI
incidence rate (p = 0.0081); CDI
decreased by 0.0047/100
bed-days per month.
Jaggi et al., 2012,
India [59] Tertiary care hospital
Antibiotic policy,
restriction, audit and
feedback
Prospective
interventional
4.03% reduction in
carbapenem-resistant
Pseudomonas. Rising trend in
E.coli, K. pnemoniae and A.
baumanniicarbapenem resistance
was recorded.
Sarraf-Yazdi et al.,
2012, USA [60]
16-bed surgical ICU at
an academic medical
center
Antibiotic cycling Controlledbefore-after
Improved susceptibility of
pseudomonal isolates to
ceftazidime (p = 0.003) and
(piperacillin/tazobactam p = 0.02).
Improved susceptibility of E. coli
to piper/tazobactam (p < 0.0005).
Nowak et al., 2012,
USA [61]
583-bed tertiary referral
hospital
Computer surveillance
& decision support
system (data-mining
software), education
Prospective
before-after
Significant decrease in rates of
CDI and VRE, (p = 0.018 and
= 0.0004 respectively). NS
difference in rate of MRSA
(p = 0.09).
Malani et al., 2013,
USA [62]
535-bed non-university
affiliated community
teaching hospital
Review, feedback,
automatic stop,
de-escalation
Retrospective
observational
Likelihood of developing CDI
decreased by 50% (p < 0.01).
Dancer et al, 2013,
UK [63]
450-bed district general
hospital
Education, restriction
following outbreak
Prospective
interventional
77% reduction in CDI rate. NS
effect on MRSA rate (p = 0.62) and
borderline effect of
ESBL-producing coliforms
(p = 0.075).
Wenisch et al., 2014,
Austria [64]
1000-bed tertiary care
community hospital
Moxifloxacin restriction,
education Before-after
46% reduction in CDI cases
(p = 0.0044).
Knudsen &
Andersen, 2014,
Denmark [65]
University hospital Guidelines, education
Controlled
before-after with
ITS
Significant reduction in
ESBL-producing K. pneumoniae
infections (p < 0.001).Significant
increase in
pipercillin-tazobactam-resistant P.
aeruginosa and E. faeciuminfections
were also recorded (p < 0.033).
Sarma et al., 2015,
UK [66]
2 acute hospitals
(combined bed 800)
Fluoroquinolone
restriction
Before-after with
ITS
Significant fall in CDI over a
60-month period.
NS—Non-significant, CRP—Ceftazidimie-resistant Pseudomonas, CDAD—Clostridium difficile associated
diarrhea, ID—Infectious diseases, MRSA—Methicillin-resistant Staphylococcus aureus, CDI—Clostridium difficile
infection, ESBL—Extended spectrum-producing beta-lactamases, VRE—Vancomycin-resistant enterococcus,
SSI—surgical site infections, EMR—Electronic medical record.
3.2.3. Impact of ASP on Patient Outcomes
Thirteen studies [68–80] were identified that reported impact on patient outcomes. Gums et al. [68]
reported shorter LOS in the intervention group than the control group (9.0 vs. 5.7; p = 0.0001) and 6.3%
mortality in the intervention group compare to 12.0% in the control group. Similarly, Ng et al. [70]
reported a significant (7.46 and 6.97 respectively; p < 0.001) difference in LOS between the periods before
and after ASP implementation with no difference in mortality. Six studies reported non-significant
difference in mortality [69,71–73,75,78].Okumura et al. [80] however reported lower 30-day mortality
with bundled ASP (intervention consisting of clinical pharmacist chart review, discussion with
microbiologist and infectious disease physicians, local education and continuous follow-up) (p < 0.01)
than conventional ASP. One study assessed incidence of adverse reactions following carbapenem
de-escalation and reported that the de-escalated group had fewer adverse reaction (11/204 (5.4%) vs.
12/96 (12.5%); p = 0.037) [79].
A summary of studies that assessed impact on patient outcomes is provided in Table 4.
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Table 4. Impact of ASP on patient outcomes.
Study Setting AMS Strategy Design Results
Gum et al., 1999,
USA [68]
275-bed community
hospital
Prospective review with
intervention Prospective RCT
Shorter LOS in the intervention
group than the control group (9.0
vs. 5.7; p = 0.0001). Mortality rate
was 12.0% (15/125) in the control
group and 6.3% (8/127) in the
intervention group.
Chang et al., 2006,
Taiwan [69] 921-bed medical center
Guidelines, restriction
and prior approval,
education
Before-after
No change in LOS, mortality and
readmission rates in the pre- and
post-intervention periods.
Ng et al., 2008,
Hong Kong [70] 1800-bed acute hospital
Guideline, antibiotic
order form, restriction,
review and feedback
Before-after
Significant difference in LOS
between pre- and post-ASP (7.46
vs.6.97 days, (p < 0.001).
NS difference in mortality (8.8%
vs. 8.4%, (p = 0.28). Significant
unplanned readmissions related
to infections post-ASP (17.6% vs.
18.7%, (p = 0.008).
Chan et al., 2011,
Taiwan [71] 3500-bed medical center
Hospital-wide
computerized
antimicrobial approval
system linked to
electronic medical
record, monitoring,
review, feedback
Prospective
interventional
Decreasing trends in mortality
over a period of 7 years 3.45%,
3.53%, 3.41%, 3.30%, 3.28%, 3.27%,
and 3.23%.
Liew et al., 2012,
Singapore [72]
1559-bed tertiary-care
hospital
Guidelines, posters,
prospective review with
intervention
Retrospective
review of ASP
interventions
Shorter LOS in patients whose
physicians accepted interventions
than those interventions were
rejected (19.9 vs. 24.2 days,
p < 0.001). NS (p = 0.191)
difference in overall mortality and
infection-related mortality
between the two groups.
Infection-related readmission and
14-day re-infection was higher in
patients whose physicians
rejected AS interventions
(p < 0.001 and p = 0.009)
respectively.
DiazGranados, C.,
2012, USA [73]
ICU at a 1000-bed
community teaching
hospital
Prospective audit with
intervention and
feedback (PAIF)
Prospective
quasi-experimental
NS (p = 0.68) difference in
mortality between patients in
intervention group and baseline.
Hospital and ICU LOS was
shorter in the PAIF group than the
baseline.
Rimawi et al., 2013,
USA [74]
24-bed medial ICU at
861-bed teaching
hospital
Review and feedback Before-after
Significant reduction in
mechanical ventilation days
(p = 0.0053), LOS (p = 0.0188), and
hospital mortality (p = 0.0367). NS
difference in medical ICU
mortality (p = 0.4970).
Lin et al., 2013,
Taiwan [75]
415-bed non-university
affiliated community
teaching hospital
Education, prospective
review with intervention
and feedback
Before-after NS difference inLOS andmortality.
Tsukamoto et al.,
2014, Japan [76]
600-bed university
teaching hospital
Daily review and
feedback Before-after
30-day mortality was lower in
post-intervention than
pre-intervention period (14.3% vs.
22.9%, p = 0.2).
Pasquale et al., 2014,
USA [77]
577-bed community
teaching hospital
De-escalation, dose
optimization, ID consult
Retrospective
review of ASP
interventions in
patients with
ABSSSIs
Mean LOS was shorter (4.4 days
vs. 6.2 days; p < 0.001) compared
to historical data. 30-day all-cause
readmission rate was lower (6.5%
vs. 16.71%, p = 0.05) in
intervention group but 30-day
ABSSSI readmission rate did not
differ between intervention and
historical groups (p = 0.483).
Rosa, Goldani &
dos Santos, 2014,
Brazil [78]
Hematology ward of
teaching hospital
ASP guidelines for
cancer patients with
febrile neutropenia
Prospective cohort
Adherence to ASP guidelines was
associated with lower mortality
(hazard ratio, 0.36; 95%
confidence interval, 0.14–0.92).
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Table 4. Cont.
Study Setting AMS Strategy Design Results
Lew et al., 2015,
Singapore [79]
1500-bed teaching
hospital
De-escalation of
carbapenem therapy
Retrospective
review of ASP
interventions
NS difference in clinical success,
survival at discharge, 30 day
mortality, 30 day readmission and
LOS between de-escalated and
non-de-escalated groups. There
was difference in
antibiotic-associated diarrhea
(4.4% vs. 12.5%; p = 0.015) the
between the two groups.
Okumura, da Silva
& Veroneze, 2015,
Brazil [80]
550-bed university
hospital
Bundled ASP
comprisingdaily review
and feedback,
de-escalation, education,
follow up till resolution
Retrospective
historical cohort
30-day mortality was lower with
bundled ASP (p < 0.01) than
conventional ASP (which
comprised passive chart review,
discussion with ID and telephone
call when intervention
was necessary).
NS—Non-significant, LOS—Length of stay, ABSSSIs—acute bacterial skin and skin structure infections.
4. Discussion
Our review identified a number of quality measures used in assessing ASP in primary studies.
These include change in antimicrobial use, cost savings, resistance patterns of some difficult to treat
organisms, rates of CDI, length of stay (LOS), readmission rate and mortality. These measures
were classified into two main categories namely process and outcome measures [20,81]. Change in
antimicrobial use (such as total quantity of antimicrobial or targeted antimicrobial class) measured
usually in the WHO recommended defined daily dose (DDD)/100 or 1000 patient-days [81] is a process
measure [4,20]. Other process measures recommended for use in assessing ASP include documentation
of indication for antibiotic prescribed, documentation of stop/review date, 48–72 hours review after
initiation of antibiotic therapy, level of adherence to hospital-specific guidelines, level of acceptance of
AMS recommendations, time to appropriate therapy in patients with sepsis, and rate of de-escalation
of initial therapy [12,14,82]. Outcome measures are categorized into microbiological, clinical and
financial outcomes [82]. Microbiological outcomes include measures such as percentage of difficult to
treat organisms e.g., MRSA, ESBL-producing Enterobacteriaceae, rate of isolation of resistant organisms,
and rate of CDI [83]. Clinical outcome measures used in assessing impact of ASP include all-cause
mortality, LOS and readmission rates; clinical improvement and rate of adverse antimicrobial reactions
have also been recommended [20,82,84].
Currently, there are no standard, universally accepted metrics for assessing ASP. For example,
DDD whilst widely used in quantifying and reporting antimicrobial use continues to be debated
because of its limitations [85]. The limitations of using DDD include its inability to provide information
on the number of patients actually exposed to antibiotics; it cannot be used for children, and it
underestimates the use for drugs that require reduced dosage due to renal impairment [85,86].
Morris et al. [18], in a structured panel to determine quality metrics for ASP, suggested days of
therapy/1000 patient-days as a more appropriate measure for public reporting of ASP impact.
Similarly, Aldeyab et al. [85] in a study that adjusted DDD to include age-adjusted comorbidity
score (DDD/100 bed-days/age-adjusted comorbidity score) concluded that the modified unit provides
“an innovative approach to measuring antibiotic use while taking into account the effect of patient case
mix”. Prescribed daily dose has also been suggested as an alternative or a complement to DDD [20].
Whether these metrics provide the appropriate standards for assessing ASP has not been determined.
However, the majority of the studies that reported significant reductions in antimicrobial use employed
DDD/1000 or 100 patient-days as the metric [24,33,34].
Assessing the impact of ASP on resistance using the identified metrics has inherent limitations.
This is because several factors affect the development of resistance, which makes it difficult to
establish a clear causal association between AMS interventions and decrease in resistance [9,20,49].
However, ASP especially those employing restriction on use of ‘high-risk’ antibiotic classes (second-
Antibiotics 2016, 5, 5 11 of 16
and third-generation cephalosprins, fluoroquinolones) have been shown to reduce resistance and/or
improve bacterial susceptibilities [47,63,65]. Although stewardship interventions have been shown to
reduce resistance, their use as a primary measure for evaluating ASP has been cautioned [87]. Rate of
CDI has been used as a measure for assessing ASP. Programs incorporating restriction or avoidance of
the ‘high-risk’ antibiotic classes and clindamycin are notably associated with significant reduction in
CDI rate [42,44,51,52,54,58,63]. Studies with marked reduction in CDI often also have strict infection
control programs in place; which makes the association between ASP and the reduction in CDI rate
difficult. However, infection control alone has been shown not to effectively control the outbreak of
CDI. A significant reduction in rates followed stewardship interventions that involved restriction or
avoidance of the ‘high-risk’ antibiotics [42,52,63].
The primary goal of ASP is to optimize patient outcomes. Six out of 13 studies included in this
review reported non-significant difference in mortality [69,71–73,75,79]. Six studies reported shorter
LOS between the pre- and post-intervention periods [68,70,72–74,77]. Notably, Ng et al. [70] reported
significant difference in LOS between the periods before and after ASP implementation (7.46 and 6.97
respectively; p < 0.001). Interestingly, the same study reported statistically significant (p < 0.001) higher
unplanned readmissions related to infections post-ASP.
Evaluation of ASP requires the use of patient-specific measures that demonstrate attainment of
the primary goal. However, some limitations affect effective evaluation. These include difficulty in
establishing a clear causal association between ASP interventions and measures such as mortality and
LOS due to confounders that affect these measures [9,20]. Mortality related to antimicrobial-resistant
organisms and infection-related hospital stay has been suggested as better patient measures for use
in assessing impact [18,70]. Lack of personnel, funds, and health information technology personnel,
and the inability to generate and analyze ASP-specific data have also been identified as limitations to
effective ASP [9,88]. Inadequate study design also limits a clear association between ASP interventions
and reported impact. Studies of interventions to improve hospital antimicrobial use are reported to be
largely of poor design [11].
This review did not apply the strict quality criteria required for a systematic review of included
studies, and risk of bias was not assessed. The purpose of this review was to provide an overview
of the quality measures used in assessing ASP in primary studies, therefore all study designs were
included. Studies assessing patient specific outcomes were of particular interest. Future work is
planned to include evaluation and impact of ASP in pediatric patients.
5. Conclusions
Patient outcomes need to be a key component of ASP evaluation. The choice of metrics is
influenced by data and resource availability. Controlling for confounders and unintended adverse
consequences must be considered in the design of evaluation studies to adequately capture the impact
of ASP. This review provides a starting pointfor compiling standard outcome metrics for assessing ASP.
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